Navigation Links
MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug"
Date:11/19/2009

MUNSTER, Germany, November 19 /PRNewswire/ -- MONITORING FORCE GmbH announced that they have filed on November 16th, 2009 Flibanserin in the indication treatment-relevant levodopa-induced dyskinesia in Parkinson's disease for orphan drug status designation with the European Medicines Agency (EMEA). Levodopa-induced dyskinesia is a complication of the mainstay treatment in advanced Parkinson's and a serious burden to some of those affected, since it may be disabling for the patients and preventing them from receiving optimal treatment for Parkinson's.

Flibanserin is a 5-HT1a agonist and a 5-HT2a antagonist and thus fits in with the current theory on levodopa-induced dysinesia that dyskinesia is caused by the release of dopamine from serotonergic neurons. MONITORING FORCE is preparing to file another orphan drug status application with the United States Food and Drug Administration (FDA) and expects the first clinical trial in Parkinson's patients to start by mid-2010.

MONITORING FORCE GmbH is a clinical research company based in Munster/Germany with affiliates in the United States, France, Italy and other countries. MONITORING FORCE does contract research for the pharmaceutical industry as well as re-purposing drug development projects on their own. MONITORING FORCE has been founded in Germany in 1995 and spread to other countries since. Parkinson's disease is a primary focus of the company.

    Contact (Company): Dr. Jurgen Beck

    General Manager, MONITORING FORCE GmbH
    Bahnhofstrasse 111, 48143 Munster, Germany
    Tel.: +49-251-214-01-30, +49-251-26-39-577 (DD)
    Fax: +49-251-21-401-53-9, Mobile: +49-171-869-82-40
    beck@monitoring-force.com,  target='_blank' title='http://www.monitoring-force.eu

'>http://www.monitoring-force.eu

    Contact (Media): Aysun Ertan
    Project Manager, Targa Communications
    Goethestrasse 22, 60313 Frankfurt am Main, Germany
    Tel.: +49-69-66-36-83-98, Fax: +49-69-66-36-83-99
    ae@targacommunications.de,  target='_blank' title='http://www.targacommunications.de

'>http://www.targacommunications.de

SOURCE MONITORING FORCE GmbH


'/>"/>
SOURCE MONITORING FORCE GmbH
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Safety in Drinking Water? Monitoring for Radioactive Contaminants Only Required Every Three, Six, or Nine Years per Federal Law
2. Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report
3. Medication Telemonitoring Improves Compliance and Behavior in NIH Study
4. Monitoring water through a snakes eyes
5. Bayers CONTOUR and Bayers BREEZE2 Blood Glucose Monitoring Systems Do Not Use Problematic GDH-PQQ Technology
6. Monitoring Circulating Tumor Cells With the CellSearch(R) System Can Predict Prognosis in Metastatic Breast Cancer
7. Monitoring water through a snakes eyes
8. Unisense FertiliTech A/S Receives CE Mark of Approval for EmbryoScope(TM) Embryo Monitoring System
9. Serial Monitoring With ImmuKnow(R) is Useful in the Risk Assessment of Kidney Transplant Recipients
10. Monitoring water through a snakes eyes
11. Sixth Annual Healthcare Unbound Conference to Focus on Remote Monitoring, Home Telehealth & eHealth for Chronic Care Management & Wellness Promotion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... Cynvenio Biosystems, Inc. a leader ... neoadjuvant breast cancer monitoring (NEAT) study in partnership with Allentown, PA-based TME Research ... patients to be monitored over two years with Cynvenio’s ClearID Breast Cancer blood test. ...
(Date:4/27/2017)... and RESEARCH TRIANGLE PARK, N.C. ... (NASDAQ: UTHR ) today announced that its ... $250 million of the company,s common stock. This program ... December 31, 2017. Purchases may be made in the ... transactions from time to time as determined by United ...
(Date:4/27/2017)... ... April 27, 2017 , ... Mitotech S.A, a Luxembourg based ... Optic Neuropathy (LHON) patients. LHON is a rare devastating genetic disease that leads to ... drops in a group of 20 patients carrying 11778, 14484 and 3460 mutations and ...
(Date:4/27/2017)... ... 27, 2017 , ... During the course of this webinar, ... 1,25-Dihydroxyvitamin D can enhance clinical practice. Participants will learn the medical indications and ... Dr. Gregory Plotnikoff, senior consultant with Minnesota Personalized Medicine, will be the speaker ...
Breaking Biology Technology:
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:3/30/2017)...  On April 6-7, 2017, Sequencing.com will host the ... hackathon at Microsoft,s headquarters in Redmond, Washington ... developing health and wellness apps that provide a unique, ... is the first hackathon for personal genomics and ... in the genomics, tech and health industries are sending ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
Breaking Biology News(10 mins):